Loading...

InMed Pharmaceuticals

TSX:IN
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IN
TSX
CA$73M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The last earnings update was 93 days ago. More info.


Add to Portfolio Compare Print
  • InMed Pharmaceuticals has significant price volatility in the past 3 months.
IN Share Price and Events
7 Day Returns
-9.6%
TSX:IN
-4.1%
CA Biotechs
-1.6%
CA Market
1 Year Returns
-57.9%
TSX:IN
-18%
CA Biotechs
-2.4%
CA Market
IN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
InMed Pharmaceuticals (IN) -9.6% -15% -30.3% -57.9% 431.3% 34.9%
CA Biotechs -4.1% -1.6% -1.4% -18% -18.8% 11.5%
CA Market -1.6% -2.3% 2.5% -2.4% 11.9% 4.6%
1 Year Return vs Industry and Market
  • IN underperformed the Biotechs industry which returned -18% over the past year.
  • IN underperformed the Market in Canada which returned -2.4% over the past year.
Price Volatility
IN
Industry
5yr Volatility vs Market

IN Value

 Is InMed Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for InMed Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is CA$0.425.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for InMed Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are InMed Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSX:IN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-0.07
TSX:IN Share Price ** TSX (2019-05-15) in CAD CA$0.43
North America Biotechs Industry PE Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 20.23x
Canada Market PE Ratio Median Figure of 549 Publicly-Listed Companies 14.56x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of InMed Pharmaceuticals.

TSX:IN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:IN Share Price ÷ EPS (both in CAD)

= 0.43 ÷ -0.07

-6.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InMed Pharmaceuticals is loss making, we can't compare its value to the North America Biotechs industry average.
  • InMed Pharmaceuticals is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does InMed Pharmaceuticals's expected growth come at a high price?
Raw Data
TSX:IN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-23.9%per year
North America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.08x
Canada Market PEG Ratio Median Figure of 250 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for InMed Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on InMed Pharmaceuticals's assets?
Raw Data
TSX:IN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$0.14
TSX:IN Share Price * TSX (2019-05-15) in CAD CA$0.43
Canada Biotechs Industry PB Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 4.7x
Canada Market PB Ratio Median Figure of 2,405 Publicly-Listed Companies 1.42x
TSX:IN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:IN Share Price ÷ Book Value per Share (both in CAD)

= 0.43 ÷ 0.14

3.01x

* Primary Listing of InMed Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • InMed Pharmaceuticals is good value based on assets compared to the CA Biotechs industry average.
X
Value checks
We assess InMed Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. InMed Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IN Future Performance

 How is InMed Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-23.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is InMed Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare InMed Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare InMed Pharmaceuticals's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare InMed Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSX:IN Future Growth Rates Data Sources
Data Point Source Value (per year)
TSX:IN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -23.9%
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 19.4%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 33.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSX:IN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSX:IN Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-06-30 0 -15 2
2019-06-30 0 -12 2
TSX:IN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 -6 -11
2018-09-30 -5 -10
2018-06-30 -5 -9
2018-03-31 -4 -7
2017-12-31 -4 -6
2017-09-30 -4 -6
2017-06-30 -3 -4
2017-03-31 -2 -3
2016-12-31 -1 -2
2016-09-30 -1 -2
2016-06-30 0 -2
2016-03-31 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • InMed Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if InMed Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSX:IN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from InMed Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:IN Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-06-30 -0.08 -0.06 -0.10 2.00
2019-06-30 -0.07 -0.06 -0.07 2.00
TSX:IN Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -0.07
2018-09-30 -0.06
2018-06-30 -0.06
2018-03-31 -0.06
2017-12-31 -0.06
2017-09-30 -0.06
2017-06-30 -0.05
2017-03-31 -0.04
2016-12-31 -0.03
2016-09-30 -0.03
2016-06-30 -0.04
2016-03-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if InMed Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess InMed Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
InMed Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IN Past Performance

  How has InMed Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare InMed Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • InMed Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare InMed Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare InMed Pharmaceuticals's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
InMed Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from InMed Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:IN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -10.65 8.24 2.71
2018-09-30 -9.54 7.39 2.18
2018-06-30 -8.52 6.56 1.93
2018-03-31 -7.37 5.55 1.73
2017-12-31 -6.48 5.02 1.35
2017-09-30 -5.88 4.67 1.10
2017-06-30 -4.47 3.63 0.75
2017-03-31 -3.10 2.59 0.42
2016-12-31 -2.27 1.87 0.31
2016-09-30 -2.10 1.70 0.31
2016-06-30 -2.38 1.91 0.38
2016-03-31 -3.32 2.58 0.65
2015-12-31 -4.54 3.38 1.08
2015-09-30 -4.33 3.26 0.98
2015-06-30 -4.29 3.25 0.94
2015-03-31 -3.92 3.20 0.64
2014-12-31 -2.40 2.18 0.17
2014-09-30 -1.87 1.73 0.11
2014-06-30 -1.23 1.17 0.06
2014-03-31 -0.18 0.15 0.03
2013-12-31 -0.08 0.07 0.02
2013-09-30 -0.04 0.05
2013-06-30 -0.05 0.05
2013-03-31 -0.13 0.10 0.02
2012-12-31 -0.13 0.11 0.02
2012-09-30 -0.17 0.12 0.02
2012-06-30 -0.19 0.15 0.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if InMed Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if InMed Pharmaceuticals has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if InMed Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess InMed Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
InMed Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IN Health

 How is InMed Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up InMed Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • InMed Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • InMed Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of InMed Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • InMed Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from InMed Pharmaceuticals Company Filings, last reported 4 months ago.

TSX:IN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 24.09 0.00 22.90
2018-09-30 25.72 0.00 24.72
2018-06-30 27.13 0.00 26.45
2018-03-31 14.70 0.00 13.85
2017-12-31 14.38 0.00 12.97
2017-09-30 7.40 0.00 6.03
2017-06-30 7.97 0.00 6.71
2017-03-31 4.12 0.00 2.73
2016-12-31 2.02 0.00 0.71
2016-09-30 1.25 0.00 0.17
2016-06-30 1.06 0.00 0.05
2016-03-31 0.65 0.00 0.01
2015-12-31 1.00 0.00 0.04
2015-09-30 1.24 0.00 0.01
2015-06-30 1.58 0.00 0.17
2015-03-31 1.14 0.15 0.05
2014-12-31 1.04 0.25 0.03
2014-09-30 1.41 0.12 0.01
2014-06-30 1.62 0.00 0.01
2014-03-31 -0.20 0.00 0.00
2013-12-31 -0.10 0.04 0.00
2013-09-30 -0.06 0.02 0.00
2013-06-30 -0.05 0.00 0.00
2013-03-31 -0.02 0.00 0.00
2012-12-31 -0.01 0.00 0.00
2012-09-30 -0.02 0.00 0.02
2012-06-30 0.00 0.00 0.05
  • InMed Pharmaceuticals has no debt.
  • InMed Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • InMed Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • InMed Pharmaceuticals has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 56.4% each year.
X
Financial health checks
We assess InMed Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. InMed Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IN Dividends

 What is InMed Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from InMed Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought CA$2,000 of InMed Pharmaceuticals shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate InMed Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate InMed Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSX:IN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.5%
Canada Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSX:IN Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2020-06-30 0.00 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as InMed Pharmaceuticals has not reported any payouts.
  • Unable to verify if InMed Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of InMed Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as InMed Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of InMed Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Canada.
X
Income/ dividend checks
We assess InMed Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can InMed Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. InMed Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IN Management

 What is the CEO of InMed Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eric Adams
COMPENSATION CA$2,574,950
AGE 55
TENURE AS CEO 2.9 years
CEO Bio

Mr. Eric A. Adams, B.S. Chem., M.I.B. has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences Corp. He has more than 15 years of experience in pharmaceutical product development, commercialization and partnerships. Mr. Adams served as the Chief Executive Officer and President of enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Mr. Adams worked with Fresenius AG (Germany) as a Country Manager for the U.S. and Italy and as Joint Venture/Acquisition Team Leader, where he expanded sales and distributions channels through numerous acquisitions and joint-ventures. He has held management positions in the pharmaceutical and biotechnology industry in North America and Europe with several companies, including Abbott Laboratories and was most recently with QLT Inc. in Vancouver. At the International Division of Abbott Laboratories, he served as Senior Business Development Manager for Anti-Infectives, where he managed all commercial, manufacturing, clinical and regulatory activities related to BIAXIN™, KLACID™. While at QLT, Mr. Adams served as the Director of Marketing for Oncology, where he managed several drug and device partnerships for Photofrin and developed new strategic opportunities through in-licensing. Previously, he served as Director of International Marketing at Advanced Tissue Sciences Inc., where he spearheaded international commercialization of Dermagraft-TC™ in the treatment of burn patients. He served as the Chairman of BIOTECanada's Emerging Company Advisory Board. He has been a Director at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Non Executive Director of enGene, Inc. since March 2004. Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies. He holds a Master of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

CEO Compensation
  • Eric's compensation has increased whilst company is loss making.
  • Eric's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the InMed Pharmaceuticals management team in years:

2.5
Average Tenure
  • The tenure for the InMed Pharmaceuticals management team is about average.
Management Team

Eric Adams

TITLE
President
COMPENSATION
CA$3M
AGE
55
TENURE
2.9 yrs

Jeff Charpentier

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$738K
TENURE
2.4 yrs

Alexandra D. Mancini

TITLE
Senior Vice President of Clinical & Regulatory Affairs
COMPENSATION
CA$693K
TENURE
2.6 yrs

Josh Blacher

TITLE
Chief Business Officer
COMPENSATION
CA$2M
AGE
45
TENURE
1.1 yrs

Eric Hsu

TITLE
Senior Vice President of Preclinical Research & Development
COMPENSATION
CA$855K
TENURE
0.3 yrs

Sazzad Hossain

TITLE
Co-Founder & Member of the Scientific Advisory Board
COMPENSATION
CA$185K

Richard Hoy

TITLE
Vice President of Sales & Marketing
TENURE
14.7 yrs

Michael Woudenberg

TITLE
Vice President
TENURE
0.5 yrs

Ado Muhammad

TITLE
Senior Consultant of Medical affairs

Paul Brennan

TITLE
Strategic Advisor
TENURE
3 yrs
Board of Directors Tenure

Average tenure and age of the InMed Pharmaceuticals board of directors in years:

2.3
Average Tenure
55
Average Age
  • The average tenure for the InMed Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bill Garner

TITLE
Chairman of the Board
COMPENSATION
CA$22K
AGE
52

Eric Adams

TITLE
President
COMPENSATION
CA$3M
AGE
55
TENURE
2.9 yrs

Sazzad Hossain

TITLE
Co-Founder & Member of the Scientific Advisory Board
COMPENSATION
CA$185K
TENURE
0.3 yrs

Adam Cutler

TITLE
Director
COMPENSATION
CA$13K
AGE
43
TENURE
3.5 yrs

Andy Hull

TITLE
Director
COMPENSATION
CA$13K
AGE
55
TENURE
2.7 yrs

Martin Bott

TITLE
Director
COMPENSATION
CA$13K
AGE
56
TENURE
2.3 yrs

Mauro Maccarrone

TITLE
Member of Scientific Advisory Board
TENURE
1.6 yrs

Vikramaditya Yadav

TITLE
Member of Scientific Advisory Board
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
18. Jan 19 Buy Eric Adams Individual 17. Jan 19 17. Jan 19 40,000 CA$0.50 CA$20,064
16. Jan 19 Buy Eric Adams Individual 16. Jan 19 16. Jan 19 10,500 CA$0.47 CA$4,917
15. Jan 19 Buy Eric Adams Individual 15. Jan 19 15. Jan 19 50,000 CA$0.48 CA$24,180
24. Aug 18 Sell William Garner Individual 20. Aug 18 24. Aug 18 -211,500 CA$0.84 CA$-164,063
22. Jun 18 Buy Eric Adams Individual 21. Jun 18 21. Jun 18 222,225 CA$0.90 CA$200,003
X
Management checks
We assess InMed Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. InMed Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IN News

Simply Wall St News

Should You Take Comfort From Insider Transactions At InMed Pharmaceuticals Inc. (TSE:IN)?

We often see insiders buying up shares in companies that perform well over the long term. … So we'll take a look at whether insiders have been buying or selling shares in InMed Pharmaceuticals Inc. … InMed Pharmaceuticals Insider Transactions Over The Last Year.

Simply Wall St -

Is InMed Pharmaceuticals Inc (TSE:IN) A Volatile Stock?

If you're interested in InMed Pharmaceuticals Inc (TSE:IN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Does InMed Pharmaceuticals Inc's (TSE:IN) Past Performance Indicate A Weaker Future?

After looking at InMed Pharmaceuticals Inc's (TSE:IN) latest earnings update (31 March 2018), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … As a long-term investor I tend to focus on earnings trend, rather than a single number at one point in time. … IN is loss-making, with the most recent trailing twelve-month earnings of -CA$7.37m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

IN Company Info

Description

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Details
Name: InMed Pharmaceuticals Inc.
IN
Exchange: TSX
Founded: 1981
CA$73,156,794
172,133,633
Website: http://www.inmedpharma.com
Address: InMed Pharmaceuticals Inc.
409 Granville Street,
Suite 340,
Vancouver,
British Columbia, V6C 1S4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX IN Common Shares The Toronto Stock Exchange CA CAD 23. Aug 1999
OTCPK IMLF.F Common Shares Pink Sheets LLC US USD 23. Aug 1999
DB MWG2 Common Shares Deutsche Boerse AG DE EUR 23. Aug 1999
Number of employees
Current staff
Staff numbers
7
InMed Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 01:26
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/03/15
Last earnings filing: 2019/02/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.